**DOCTOR’S ORDERS**

| Ht cm | Wt kg | BSA m² |

**REMINDER:** Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form.

**DATE:**

| To be given: | Cycle #: |

Date of Previous Cycle:

- □ Delay treatment ______ week(s)
- □ CBC & Diff and Platelets day of treatment

May proceed with doses as written if within 96 hours **ANC greater than or equal to 1.2 x 10⁹/L, Platelets greater than or equal to 100 x 10⁹/L**

Dose modification for:
- □ Hematology
- □ Other Toxicity ________________________________

Proceed with treatment based on blood work from ________________________________

**PREMEDICATIONS:** Patient to take own supply. RN/Pharmacist to confirm ________________________________.

- ondansetron 8 mg PO prior to treatment
- dexamethasone 8 mg or 12 mg (circle one) PO prior to treatment
- □ Other:

**CHEMOTHERAPY:**

- predniSONE 100 mg PO daily in AM with food on days 1 to 5.
- vinCRIStine 1.4 mg/m² x BSA = __________ mg
- □ Dose Modification: _______% = _______ mg/m² x BSA = __________ mg
  - IV in 50 mL NS over 15 mins.
  - cyclophosphamide 1000 mg/m² x BSA = __________ mg
  - IV in 100 to 250 mL NS over 20 minutes to 1 hour.

**RITUXIMAB WITHIN 72 HOURS OF CVP**

**PREMEDICATIONS:** Patient to take own supply. RN/Pharmacist to confirm ________________________________.

**For intravenous riTUXimab infusion:**

- diphenhydrAMINE 50 mg PO prior to riTUXimab IV and then q 4 h if IV infusion exceeds 4 h
- acetaminophen 650 mg to 975 mg PO prior to riTUXimab IV and then q 4 h if IV infusion exceeds 4 h
- predniSONE as ordered for the LYCVPR protocol

**For subcutaneous riTUXimab injection:**

- diphenhydrAMINE 50 mg PO prior to riTUXimab SC
- acetaminophen 650 mg to 975 mg PO prior to riTUXimab SC
- predniSONE as ordered for the LYCVPR protocol

**DOCTOR’S SIGNATURE:**

| SIGNATURE: | UC: |
**Have Hypersensitivity Reaction Tray and Protocol Available**

**TREATMENT:** (continued) **TREATMENT #1:**
riTUXimab IV or SC may be given before or after chemotherapy, but within 72 hours of CVP

**riTUXimab (first dose) 375 mg/m^2 x BSA = __________ mg**
- IV in 250 to 500 mL NS within 72 hours after day 1 of CVP. Start at 50 mg/hour.
- After 1 hour, increase rate by 50 mg/hr every 30 minutes until rate = 400 mg/h unless toxicity occurs.

For the first dose, patients are to be under constant visual observation during all dose increases and for 30 minutes after infusion completed. Vital signs are not required, unless symptomatic.

**FOR ALL SUBSEQUENT TREATMENTS:**
- □ Patient tolerated a full dose of IV riTUXimab (no severe reactions requiring early termination) and can proceed to subcutaneous riTUXimab:
  - **riTUXimab (subsequent dose) 1400 mg (fixed dose in 11.7 mL) subcutaneously** into abdomen over 5 minutes.
  - Observe for 15 minutes after administration.

- NB: During treatment with subcutaneous riTUXimab, administer other subcutaneous drugs at alternative injection sites whenever possible.

- □ Patient did not tolerate a full dose of IV riTUXimab (experienced severe reactions requiring early termination) in the previous treatment and will continue with IV riTUXimab for this cycle:
  - **riTUXimab (subsequent dose) 375 mg/m^2 x BSA = __________ mg**
  - IV in 250 to 500 mL NS. Infuse 50 mL (or 100 mL of 500 mL bag) of the dose over 30 minutes, then infuse the remaining 200 mL (or 400 mL of 500 mL bag) over 1 hour.

  If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page physician.

  For all subsequent doses, constant visual observation is not required.

**RETURN APPOINTMENT ORDERS**
- □ Return in **three or four** weeks (circle one) for Doctor and Cycle _________
- □ Last Cycle. Return in _______ week(s).

**CBC & Diff, platelets** prior to each cycle
- □ Other tests:
- □ Consults:
- □ See general orders sheet for additional requests.

**DOCTOR’S SIGNATURE:**

**SIGNATURE:**

**UC:**